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Background: Heart disease and stroke are two leading causes of disability and death in the United States. The
Mediterranean diet has been shown to reduce recurrent cardiovascular events and decrease inflammatory
biomarkers that contribute to atherosclerotic progression. Should the Mediterranean diet be recommended to
patients with known risk factors for cardiovascular disease to reduce risk of first incident or mortality
associated with cardiovascular and cerebrovascular disease?
Methods: An exhaustive search of available medical literature was conducted using Medline-OVID, CINAHL
and EBSCO-Host. The key words that were used individually and in combination included: Mediterranean
diet, vascular inflammation, cardiovascular disease treatment, cerebrovascular disease, coronary heart disease,
myocardial infarction, CRP and IL-6. Relevant articles were assessed for quality using GRADE.
Results: Three studies met inclusion and exclusion criteria and were used in this review. The first is a large
prospective Greek-population cohort study, which found a decrease in mortality from coronary heart disease
with greater Mediterranean diet adherence. The second is a large prospective Manhattan-population cohort
study, which found no association for diet adherence and ischemic stroke and a reduced risk of myocardial
infarction and vascular death up to a score of four. The third is a large prospective Mediterranean-population
based cohort study, which found a reduction in cerebrovascular incident with diet scores greater than four.
Conclusion: The Mediterranean diet has been shown to reduce the risk of cardiovascular disease incidence
and mortality. There is conflicting evidence regarding reduction of cerebrovascular disease incidence and
mortality. The overall study quality is very low due to design and follow up time, however, a dose response
gradient is evident in each study. Providers should advise patients without disease but with known risk factors
to implement complete adherence to the Mediterranean diet for best risk reduction.
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Abstract   
Background: Heart disease and stroke are two leading causes of disability and death in 
the United States. The Mediterranean diet has been shown to reduce recurrent 
cardiovascular events and decrease inflammatory biomarkers that contribute to 
atherosclerotic progression. Should the Mediterranean diet be recommended to patients 
with known risk factors for cardiovascular disease to reduce risk of first incident or 
mortality associated with cardiovascular and cerebrovascular disease? 
 
Methods: An exhaustive search of available medical literature was conducted using 
Medline-OVID, CINAHL and EBSCO-Host. The key words that were used individually 
and in combination included: Mediterranean diet, vascular inflammation, cardiovascular 
disease treatment, cerebrovascular disease, coronary heart disease, myocardial infarction, 
CRP and IL-6. Relevant articles were assessed for quality using GRADE. 
 
Results:  Three studies met inclusion and exclusion criteria and were used in this review. 
The first is a large prospective Greek-population cohort study, which found a decrease in 
mortality from coronary heart disease with greater Mediterranean diet adherence. The 
second is a large prospective Manhattan-population cohort study, which found no 
association for diet adherence and ischemic stroke and a reduced risk of myocardial 
infarction and vascular death up to a score of four. The third is a large prospective 
Mediterranean-population based cohort study, which found a reduction in 
cerebrovascular incident with diet scores greater than four. 
 
Conclusion: The Mediterranean diet has been shown to reduce the risk of cardiovascular 
disease incidence and mortality. There is conflicting evidence regarding reduction of 
cerebrovascular disease incidence and mortality. The overall study quality is very low 
due to design and follow up time, however, a dose response gradient is evident in each 
study. Providers should advise patients without disease but with known risk factors to 
implement complete adherence to the Mediterranean diet for best risk reduction. 
 
Keywords: Mediterranean diet, myocardial infarction, cerebrovascular disease, coronary 
heart disease, vascular inflammation.  
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The Efficacy of a Mediterranean Diet in Reducing the Risk of Cardiovascular 
Disease Progression in Patients with Known Risk Factors 
 
BACKGROUND 
 Heart disease and stroke are two of the leading causes of disability and death in 
the United States, with an estimated one in three adults being affected and over 811 000 
deaths occurring annually (http://www.heart.org/idc/groups/heart-
public/@wcm/@adt/documents/downloadable/ucm_449081.pdf).1 This statistic has 
increased from American Heart Association (AHA) statistics in 2005, where one in five 
deaths were attributed to coronary heart disease (CHD).2 Camargo et al3 describes 
cardiovascular disease (CVD) as an inflammatory process caused by aging, oxidative 
stress, and an increase in pro-inflammatory molecules which are affected by dietary fat 
intake. An important factor in atherosclerotic development is plaque stability, as rupture 
of plaque particles can cause significant cardiovascular (CV) events like myocardial 
infarction (MI), cerebrovascular disease (CBVD) like stroke, and death. Camargo et al3 
describes the determining factors of plaque stability and rupture as chronic lipid 
accumulation within the vascular endothelium, chronic low-grade inflammation, and 
subsequent weakening of plaque caps over time. Patients most at risk for CVD or CBVD 
incidents are males over the age of 45, females over the age of 55, current smokers, high-
density lipid value less than 40, stage one hypertension, or use of hypertensive 
medication and family history of coronary artery disease (CAD). 
 Therapeutic lifestyle changes (TLC) are first line therapy for those at risk and 
with a current diagnosis of heart disease, however there are many dietary 
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recommendations available that can be confusing to providers when advising patients on 
how to improve their long term health. Past dietary recommendations by the AHA, 
National Cholesterol Education Program (NCEP), and Adult Treatment Panel III (ATP 
III) have failed to reduce the incidence of CHD, which prompts investigation into 
developing other, more effective, dietary guidelines.2 Extensive research on the 
traditional Mediterranean diet (MD) has been completed over the last 60 years since 
Ancel Keys, a U.S. nutritionist, concluded that death from CHD was lower in 
Mediterranean populations compared with other areas of the world.2 According to the 
AHA, an MD consists of high consumption of fruits, vegetables, bread and other cereals, 
potatoes, beans, nuts and seeds, olive oil as the main fat source, low to moderate intake of 
dairy products, fish and poultry, little intake of red meat, none or little intake of eggs, and 
low to moderate intake of wine (see Figure 1). The MD has been studied extensively for 
its ability to decrease the incidence of future CV events in patients with existing CVD or 
previous MI.4,5 Many studies have been performed that measure short term (<2 years) 
outcomes like inflammatory markers, immune cell activation, pro-atherogenic genes, and 
endothelial function in patients who adhere to the MD.3,6,7 Although these studies showed 
improved outcomes with MD intervention, long term (>5years) evidence of risk reduction 
is necessary to evaluate the sustainability of such a recommendation. It is also important 
to consider a population without disease to evaluate the ability of the MD to prevent 
incidents in those patients most at risk. Evidence of a decrease in incident of CV and 
cerebrovascular events in patients with known risk factors for CVD but without current 
disease diagnosis is important to consider when advising patients on effective lifestyle 
changes. The goal of preventative medicine is to make lifestyle changes that prevent 
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these events from ever occurring, and the MD seems to be a viable option for disease 
prevention. Should the MD be recommended to patients with known risk factors for CVD 
to reduce risk of incident or mortality associated with cardiovascular and cerebrovascular 
disease? 
METHODS 
 An exhaustive search of available medical literature was conducted using 
Medline-OVID, CINAHL and EBSCO-Host using the following key words individually 
or in combination: Mediterranean diet, vascular inflammation, cardiovascular disease 
treatment, cerebrovascular disease, myocardial infarction, CRP, and IL-6. The search was 
narrowed to include only studies with a mean follow-up time greater than five years, 
published no sooner than 2008, that were either randomized controlled trials, cohorts, or 
randomized crossover studies, in the English language, and only on human subjects. 
Articles evaluating patient populations without current or previous diagnosis of CVD or 
CBVD were included. Relevant articles were assessed for quality using the Grading of 
Recommendations, Assessment, Development and Evaluation (GRADE).8 
RESULTS 
 The initial search yielded 130 articles for review. After assessing the articles for 
relevancy, nine articles were further reviewed based on inclusion criteria. Of these, three 
articles met both inclusion and exclusion criteria. All three articles are large prospective 
cohort studies.9-11 See Table 1. 
Dilis, et al 
 10 
 
 This large population-based prospective cohort study9 assessed the association 
between MD adherence and CHD incidence and mortality in a Greek population. This 
population was a subgroup of the EPIC cohort (European Prospective Investigation into 
Cancer and Nutrition), a large database of 520 000 participants from ten European 
countries. The EPIC cohort “provides data on diet, anthropometry, lifestyle, socio-
economic variables, as well as genetic and biomarker data in relation to cancer and other 
chronic diseases.” Primary outcomes measured were CHD incident which included 
angina, myocardial infarction or other CHD event. Mortality was measured if the CV 
event resulted in death.9 
 The Greek segment of the EPIC cohort consists of 28 572 male and female 
participants. Participants were excluded if they had a previous diagnosis of CVD or 
cancer at time of enrollment, if follow up data was insufficient, or if patients were not 
able to provide data for one or more of the study variables. The final study consisted of 
23 929 participants (9740 men and 14 189 women) who met eligibility criteria. All 
participants signed an informed consent and the study was approved by the International 
Agency for Research on Cancer and the Medical School of the University of Athens 
ethics committee.9 
 The intervention assessed was adherence to a traditional MD, which ranged from 
non-adherent to completely adherent. Baseline data collected included dietary habits for 
each participant using a quantitative food questionnaire administered by an interviewer 
that assessed intake and frequency of intake of 200 of the most common Greek foods. 
Portion sizes were confirmed with photographs. MD adherence was assessed using a 10-
point score as developed by Trichopoulou et al.12 A score of zero or one was assigned to 
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those who did not frequently or who frequently consumed foods typical of the MD, 
respectively (vegetables, legumes, fruits and nuts, cereals, fish and seafood, high ratio of 
monounsaturated to saturated fats). A score of zero or one was given to those who 
frequently or infrequently consumed foods not consistent with the MD, respectively 
(dairy, meat or meat products). A score of one was assigned to those consuming a 
moderate amount of alcohol daily, and a score of zero was assigned otherwise. A score of 
zero correlated with non-adherence and a score of nine correlated with complete 
adherence to the MD. Participants were grouped into three score ranges (0-3, 4-5, 6-9) 
based on frequency of consumption of these nine different food types. Patient 
characteristics were also recorded at baseline and included the following: age, years of 
schooling, height, BMI, level of physical activity, alcohol intake, smoking status, and 
blood pressure.9 
 Follow up was completed via telephone interviews by “specially trained health 
professionals” although no indication of blinding is discussed. There is also no mention 
of the frequency of follow up with each participant. Next of kin was contacted in the 
event of participant death during the follow up period. Outcomes reported by participants 
or next of kin during the follow up period were confirmed via hospital discharge data, 
medical records or death certificates.9 
 The association between MD and outcome measures (MI, angina and CHD other 
than MI, or angina and death) was assessed using Cox regression and adjusted for age, 
BMI, height, physical activity, years of schooling, energy intake, and sex. Over a mean 
follow up period of 10 years, 636 volunteers developed CHD (426 males and 210 
females), and 240 of these people died from the disease (150 males and 90 females). The 
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study recognized certain baseline characteristics of the participants, such as there being 
more women than men in the study, a greater percentage of participants with lower 
education level, and most participants being overweight or obese.9 
 Independent of MD adherence, the association between risk factors for CHD and 
CHD incidence and mortality were assessed for men and women separately. These risk 
factors for CHD include age > 45 for men, > 55 for women, current smokers and 
hypertension (HTN). For men, there was a statistically significant 2-fold, 3-fold and 6-
fold increase in CHD incidence at 45-54 years, 55-64 years, and > 65 years old, 
respectively, and a 3-fold and 14-fold increase in CHD mortality at 55-64 years and > 65 
years old, respectively. Male smokers and with Stage 1 HTN or on hypertensive agents 
were at a statistically significant 2-fold increased risk of CHD incidence and mortality 
(see Table 2). For women, there was a statistically significant 6-fold and 12-fold increase 
in CHD incidence at 55-64 years and > 65 years old, respectively, and a 9-fold and 36-
fold increase in CHD mortality at 55-64 years and > 65 years old, respectively. Female 
smokers were at a statistically significant 2-fold increased risk of CHD incidence and 
mortality. Females with Stage 1 HTN or on hypertensive agents were at a statistically 
significant 3-fold increased risk of CHD incidence and 2-fold risk of CHD mortality (see 
Table 3).9 
 In regards to MD adherence and CHD incidence and mortality, after being 
adjusted for sex, age, BMI, height, physical activity, years of schooling, and energy 
intake, a statistically significant reduction in CHD mortality was seen in those 
participants with MD scores of 6-9. There was a “suggestive reduction” in CHD 
incidence with greater adherence to the MD (scores 4-5 and 6-9), indicating a dose 
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response gradient. When applying a 2-point increase to the MD scores to assess if greater 
adherence had an effect on incidence and mortality, there was a statistically significant 
25% reduction in CHD mortality among women and 19% reduction in CHD mortality 
among men.9 See Table 4. 
Gardener et al 
 This large population-based prospective cohort study10 assessed the relationship 
between MD adherence and risk of stroke incidence, MI incident, and vascular death in 
white, black, and Hispanic communities in Manhattan, New York. The study was derived 
from the NOMAS cohort study, which was designed to evaluate stroke incidence in 
relation to risk factors and prognosis in Manhattan communities. Primary outcomes 
measured were ischemic stroke incidence, MI incidence, and vascular death.10  
 Eligible participants included those who did not have a previous incident of 
ischemic stroke, were > 40 years of age, and had lived in Northern Manhattan for at least 
3 months with telephone access. Participants with a history of MI prior to enrollment 
were excluded. Participants were contacted via random-digit dialing and interviewed by 
trained bilingual interviewers and research assistants. An in-person baseline interview 
and assessment by study neurologists was conducted after the telephone interview. A 
total of 2568 participants were included in the study. All participants signed an informed 
consent and the study was approved by the Columbia University and University of Miami 
review boards.10 
 The intervention assessed was adherence to the MD, as determined by a modified 
Block National Cancer Institute food-frequency questionnaire given by bilingual research 
assistants. Due to the overwhelming Hispanic population percentage in the study group, 
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the food-frequency questionnaire was modified to include Hispanic foods. Each 
participant was assigned a value of one for each of the following foods consumed at or 
above the median: fruit, vegetables, legumes, cereals and fish. A value of one was 
assigned for meat and dairy products if consumed at or below the median. A value of one 
was assigned if the ratio of monounsaturated to saturated fats was at or above the median, 
and for mild-to-moderate alcohol consumption. Participants were categorized into 
quintiles (0-2, 3, 4, 5, 6-9) based on their responses. A higher response correlated to 
greater adherence to the MD. Baseline assessment was completed using standardized 
questions from the Behavioral Risk Factor Surveillance System by the CDC. Risk factor 
evaluation included presence of hypertension, diabetes, hyperlipidemia, and low level of 
physical activity.10 
 Participants were followed up with annually by telephone to assess for “changes 
in vital status, detect neurologic events, document interval hospitalizations, and review 
risk factor status, medication changes, and changes in functional status.” If a positive 
response was found, an in-person interview with neurologic assessment was completed. 
Incident events were confirmed via hospital discharge records.10 
 The association between adherence and outcome measures (stroke, MI, and 
vascular death) was assessed using chi-square tests, ANOVA, Cox hazard models and 
95% CI, and adjusted for age, sex, race-ethnicity, education, moderate-to-heavy physical 
activity, average total daily kilocalorie consumption, and smoking. A second model 
adjusted for these variables and confounders like diabetes (DM), HTN, 
hypercholesterolemia and history of self-reported CV disease. A binary variable was used 
to account for missing dietary data in attempts to minimize potential bias. Additionally, 
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participants reporting <500 or >4000 kilocalorie intake values were excluded, as this was 
likely inaccurate reporting of dietary intake. Over a mean follow up period of 9 +/- 3.5 
years, 518 vascular events occurred, which included 171 ischemic strokes, 133 
myocardial infarctions, and 314 vascular deaths.10 
 In regards to MD adherence and outcome events, no significant association was 
found for MD adherence and reduced risk of ischemic stroke. For MI, there was a 
decreased risk of event up to an MD score of four, at which point higher MD adherence 
seemed to provide no additional risk reduction indicating a threshold effect without a 
dose-response relationship. These results were not statistically significant. For vascular 
death, there was a decreased risk of event up to an MD score of four as well, and beyond 
this score there was a similar threshold effect. These results were also not statistically 
significant. When applying a 1-point increase to the MD score, there was a 9% decrease 
in risk of vascular death. When evaluating the association between MD and all events 
combined, statistical significance was achieved only for MD scores of 4 and 5, however, 
there was risk reduction evident for scores >3 with threshold effect beyond a score of 
four. In addition, those in the highest quintile (6-9) experienced the greatest risk 
reduction in vascular event (33%) compared to the lowest quintile (0-2). The study 
suggests a possible threshold effect beyond the 3rd quintile.10 See Table 4.  
Miserli et al 
 This large population-based prospective cohort study11 assessed the association 
between MD adherence and risk of incidence and mortality from cerebrovascular disease 
(CBVD), specifically ischemic vs. hemorrhagic stroke. This population was a subgroup 
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of the EPIC cohort. Primary outcomes were CBVD incident (ischemic stroke and 
hemorrhagic stroke) and CBVD mortality.11 
 Participants were invited volunteers from the general Greek population who were 
already participants in the Greek EPIC cohort. Participants were excluded if they had a 
history of CBVD, CVD, or cancer at time of enrollment and insufficient follow up due to 
loss of contact or missing variable information like socio-economic, lifestyle, dietary, or 
anthropometric data. The final study included 23 601 participants who met eligibility 
criteria. All participants signed an informed consent and the study was approved by the 
University of Athens Medical School Bioethics Committee.11 
 The intervention assessed was MD adherence. Baseline dietary data was collected 
by interviewers who recorded participant’s dietary habits after a validated 
semiquantitative food frequency questionnaire which included about 150 food and drink 
items common to the traditional Greek diet. Participants visited the study center every 
month for one year to give a 24-hour recall of their diet to assess habits. Participants were 
assigned to an MD adherence group (0-3, 4-5, 6-9) based on Trichopoulou et al’s12 study 
design after assessment of baseline dietary habits was completed. Baseline characteristics 
like physical activity, blood pressure, health problems, medication use, and smoking 
habits were recorded as well.11 
 Follow up was conducted by telephone to record changes in health status, diet, 
and lifestyle. Next of kin was contacted in the event of death of a participant. The study 
admits to lack of information on lifestyle changes for a large percentage of the study 
participants. Outcomes reported by participants or next of kin were confirmed by hospital 
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records, discharge data, or death certificates. Local death registries were consulted to 
confirm cause of death.11 
 The association of MD adherence and outcome measures (ischemic stroke, 
hemorrhagic stroke, and mortality) were analyzed using Cox regression models and 
Nelson-Aalen cumulative hazard curves, with controlling for sex, age, education, 
smoking status, BMI, level of physical activity, HTN, DM, and total energy intake. Data 
was analyzed with the STATA SE statistical package, 11th edition. Over a mean follow 
up period of 10.6 years, 395 first-ever CBVD events occurred and 1446 deaths occurred, 
with 196 of those being due to CBVD.11  
 Independent of MD adherence, the association between known risk factors for 
CHD and CBVD incidence and mortality were assessed for the participants. For 
participants aged 55-64, there was a statistically significant 3-fold and 4-fold increase in 
CBVD incident and mortality, respectively. For those aged > 65, there was a statistically 
significant 9-fold and 18-fold increase in risk of incidence and mortality, respectively. 
There was no statistical significant increase in incident and mortality for current smokers 
or those with BMI >25. For participants with HTN, there was a statistically significant 
1.39x risk of CBVD incident and no statistical significance in mortality. This was the 
same for participants with diabetes (DM), with a statistically significant 1.44x risk of 
CBVD incident without statistically significant risk of mortality (see Table 5).11 
 In regards to MD adherence and CBVD incidence and mortality, after being 
adjusted for sex, age, education, smoking status, BMI, level of physical activity, HTN, 
DM, and total energy intake, a statistically significant reduction in CBVD incident was 
seen in those participants with MD scores of >4. There is a suggestive reduction in 
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mortality, however, not statistically significant. A dose-response gradient was observed 
with an inverse relationship between increased adherence to the MD and decreased 
incident and mortality (see Table 4).11 
 In regards to incidence of ischemic versus hemorrhagic versus overall CBVD, 
after being adjusted for the same variables as above, the greatest risk reduction was seen 
in those in the MD score 6-9 category. Overall CBVD reduction was statistically 
significant, whereas ischemic was marginally significant versus hemorrhagic that was not 
significant. An inverse relationship between MD score and reduction of event or 
mortality was event for both ischemic and hemorrhagic stroke, indicating a dose response 
gradient. When applying a 2-point increase to the MD score to assess if greater adherence 
had an effect on incidence and mortality, there was a statistically significant reduction in 
CBVD incident only (HR = 0.85, 95% CI = 0.74, 0.96) (see Table 4).11  
DISCUSSION 
 The Mediterranean diet has been shown in multiple studies as an effective 
intervention for the secondary prevention of CVD and CBVD events, improvement in 
endothelial function, decreasing inflammatory biomarkers, and decreasing the expression 
of pro-atherogenic genes.3-7 ideally, providers should have a dietary recommendation for 
patients who do not have a diagnosis of CVD or CBVD in order to prevent these events 
from occurring. These three large prospective cohort studies9-11 provide insight into the 
MD efficacy in reducing incidence and mortality in patients without CVD or CBVD 
diagnosis, and with risk factors for disease to help answer the question: Should the MD 
be recommended to patients with known risk factors for CVD to reduce risk of incident 
or mortality associated with cardiovascular and cerebrovascular disease? 
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Clinical Relevance 
 When comparing patient risk factors (age, smoking status, HTN, DM, BMI) with 
CVD and CBVD incidence and mortality, Dilis et al9 and Misirli et al11 found a 
statistically significant increase in events with increasing age. Dilis et al9 found an 
increase in incidence and mortality in current smokers and patients with HTN, with a 
particularly higher incidence in women. Misirli et al11 did not find statistically significant 
increase in events of smokers or those with a BMI >25. There was only a statistically 
significant increase in incidence, not mortality, in patients with DM and HTN11 (see 
Tables 2-3, 5). These results, though not identical, support the rationale that patients with 
risk factors for CVD and CBVD are generally at a higher risk of either incident or 
mortality. This generalization supports the need to find an appropriate dietary 
recommendation for patients at risk to prevent future events from occurring. 
 When comparing MD adherence and CVD and CBVD incident and mortality, 
Dilis et al9 found a statistically significance reduction in mortality only with MD scores 
of 6-9, indicating a dose response gradient. When a 2-point increase in the MD score was 
applied to the data, a 25% decrease in mortality in women and 19% decrease in mortality 
in men was found.9 Gardener et al10 found no association between MD adherence and 
stroke incident, and a threshold effect beyond an MD score of 3 for MI incident, vascular 
death and overall events. When comparing MD scores of 0-2 (least adherent) to MD 
scores of 6-9 (most adherent), a dose-response gradient is evident by a 33% decrease in 
event.10 Misirli11 et al found a statistically significant decrease in CBVD incident with an 
MD score greater than 4, again indicating a dose-response gradient. Overall event 
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(ischemic and hemorrhagic stroke) was decreased most with an MD score of 6-9 and was 
statistically significant, however when assessed independently, ischemic stroke was 
“marginally” significant and hemorrhagic stroke was not statistically significant.11 All 
three studies9-11 recognize that greater adherence to the MD point toward a decrease in 
either incident of or mortality from CVD or CBVD events. Though not all data is 
statistically significant, a generalization can be made that this dietary recommendation 
would likely benefit patients at risk for CVD and CBVD (see Table 4). 
Limitations 
 All three studies9-11 are limited by design. Each is a large prospective population-
based cohort and lacks a control group. Each study has the potential for recall bias, since 
follow up times for each are long (>9 years). In addition, Dilis et al9 and Gardener et al10 
do not mention blinding of interviewers or neurologists. Dilis et al9 and Misirli et al11 do 
not mention frequency of follow up for each participant (see Table 1). The combination 
of these limitations downgrades each study to a very low quality status based on GRADE 
criteria.8 Dilis et al9 does not provide recommendations for future studies. Gardener et 
al10 recommends further studies in larger populations to evaluate the association between 
MD and stroke. Misirli et al11 recommends more studies to replicate the protective effect 
of the MD against ischemic CBVD, as this was an unexpected finding.11 
CONCLUSION 
 The Mediterranean diet has been demonstrated to reduce the risk of incident and 
mortality in patients at risk of developing CVD or CBVD. Patients with known risk 
factors for CVD are at a much greater risk of event and worse, mortality from an event. 
The overall combined quality of the studies reviewed is very low based on GRADE 
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criteria8 due to cohort study design and long follow up periods that allow potential for 
recall bias. However, each study provides evidence of a dose-response gradient, where 
better risk reduction can be achieved with greater adherence to the diet.  
 Since there is no harm in implementing the Mediterranean diet, it should be 
recommended by providers as a preventative measure when advising patients about 
lifestyle changes prior to an event, with emphasis on the long term value of complete 
adherence rather than mild or moderate adherence to achieve the best risk reduction. 
However, even some adherence to the MD is beneficial. For patients with risk factors for 
heart disease and stroke but without a current diagnosis, implementing a lifestyle change 
now rather than waiting for an event to occur would greatly reduce risk of event or 
mortality from an event. Research studies that implement a randomized controlled trial 
design with monthly follow up frequency over several years would provide more concise 
outcomes. 
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Table 1. Characteristics of Reviewed Studies 
Quality Assessment 
 Downgrade Criteria Quality Importance 
No. of 
Studies 
Design Limitations Indirectness Imprecision Inconsistency Publication 
Bias Likely 
Cerebrovascular Disease Incident (Ischemic and Hemorrhagic Stroke)   
2 Prospective 
Cohort 
No control, 
potential 
for recall 
bias 
No 
indirectness 
No lack of 
precision 
No 
inconsistencies Unlikely 
Very 
Low Important 
Cerebrovascular Disease Mortality   
1 Prospective 
Cohort 
No control, 
potential 
for recall 
bias 
No 
indirectness 
No lack of 
precision 
No 
inconsistencies Unlikely 
Very 
Low Critical 
Coronary Heart Disease Incident (MI, angina)   
2 Prospective 
Cohort 
No control, 
potential 
for recall 
bias 
No 
indirectness 
No lack of 
precision 
No 
inconsistencies Unlikely 
Very 
Low 
 
Important 
Coronary Heart Disease Mortality   
2 Prospective 
Cohort 
No control, 
potential 
for recall 
bias 
No 
indirectness 
No lack of 
precision 
No 
inconsistencies Unlikely 
Very 
Low 
 
Critical 
 
Table 2. Risk Factors and CHD Incidence and Mortality - Men 
Age CHD Incidence CHD Mortality 
 HR 95% CI Statistically 
Significant? 
HR 95% CI Statistically 
Significant? 
45-54 2.32 1.62, 3.32 Y 1.99 0.86, 4.61 N 
55-64 3.48 2.39, 5.08 Y 3.04 1.31, 7.06 Y 
>65 5.69 3.79, 8.54 Y 13.75 6.03, 31.36 Y 
Current Smoker 2.01 1.56, 2.61 Y 2.22 1.43, 3.43 Y 
HTN Stage 1 or 
HTN medication 
use 
1.63 1.30, 2.03 Y 1.62 1.09, 2.40 Y 
*Dilis et al 
 
Table 3. Risk Factors and CHD Incidence and Mortality - Women 
Age CHD Incidence CHD Mortality 
 HR 95% CI Statistically 
Significant? 
HR 95% CI Statistically 
Significant? 
55-64 5.72 3.09, 10.59 Y 9.26 2.54, 33.80 Y 
>65 12.18 6.51, 22.82 Y 36.14 10.02, 130.39 Y 
Current 
Smoker 
1.89 1.10, 3.23 Y 2.35 1.03, 5.34 Y 
HTN Stage 1 
or HTN 
medication use 
2.62 1.76, 3.90 Y 1.88 1.05, 3.34 Y 
*Dilis et al 
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Table 4. Summary of Findings 
 Number of Patients  Outcomes 
Study Treatment 
(total) 
Placebo or no 
treatment 
(total) 
MD score CHD Incident (MI, angina, 
other acute/chronic ischemic 
heart disease, n=636) 
CHD Mortality (n=240) 
 
 
Dilis et al 
 
 
23 929 * 
 HR 95% CI HR 95% CI 
0-3 1 Reference 1 Reference 
4-5 0.86 0.72, 1.03 0.82 0.62, 1.09 
6-9 0.82 0.66, 1.02 0.54 0.37, 0.81 
    CBVD Incident 
(Ischemic stroke, 
n=171) 
CHD Incident (MI, 
n=133) 
CHD Mortality 
(Vascular death, 
n=314) 
 
 
Gardener et 
al 
 
 
2568 
 
 
* 
0-2 1 Reference 1 Reference 1 Reference 
3 1.18 0.69, 2.01 0.57 0.32, 1.03 0.87 0.60, 1.26 
4 0.91 0.53, 1.55 0.62 0.37, 1.06 0.74 0.52, 1.06 
5 0.96 0.56, 1.63 0.60 0.34, 1.04 0.69 0.47, 1.00 
6-9 1.03 0.61, 1.73 0.65 0.38, 1.12 0.71 0.49, 10.4 
    CBVD Incident 
(Ischemic Stroke, 
n=95) 
CBVD Incident 
(Hemorrhagic 
Stroke, n=59) 
CBVD Mortality 
(n=196) 
 
Misirli et al 23 601 
 
* 
0-3 1 Reference 1 Reference 1 Reference 
4-5 0.77 0.50, 1.21 1.25 0.69, 2.26 0.79 0.57, 1.08 
6-9 0.54 0.29, 1.01 0.86 0.40, 1.87 0.76 0.50, 1.16 
 
Table 5. Risk Factors and CBVD Incidence and Mortality 
 
Age CBVD Incidence CBVD Mortality 
 HR 95% CI Statistically 
Significant? 
HR 95% CI Statistically 
Significant? 
55-64 3.32 2.22, 4.97 Y 3.56 1.77, 7.15 Y 
>65 9.29 6.21, 13.88 Y 17.50 8.97, 34.15 Y 
Current Smoker 1.23 0.90, 1.68 N 1.50 0.96, 2.36 N 
NHTN Stage 1 or 
HTN medication 
use 
1.39 1.09, 1.77 Y 1.35 0.95, 1.93  
DM 1.44 1.16, 1.79 Y 1.32 0.97, 1.79 N 
*Misirli et al 
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Figure 1. Mediterranean Diet Pyramid 
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